Oobli Scales Fermented Sweet Proteins for Metabolic Formulations
Oobli is commercialising bio-identical sweet proteins via precision fermentation, offering formulators an insulin-neutral, gut-friendly alternative to sugar and polyols.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
Davis, United States — 28 May 2024. Precision fermentation specialist Oobli is accelerating the commercialisation of bio-identical sweet proteins, positioning the ingredient group as a functional replacement for both caloric sugars and synthetic high-intensity sweeteners in metabolic wellness products.
According to Amy Chen, president and chief commercial officer at Oobli, the company utilises yeast-based fermentation to produce proteins identical to those found in rare equatorial fruits, including miraculin. Unlike polyols and synthetic sweeteners that frequently cause digestive upset or unintended insulin responses, sweet proteins undergo normal peptide digestion, breaking down into standard dietary amino acids. This metabolic mechanism avoids blood glucose surges, providing functional utility for blood sugar control and weight management formulations.
From a manufacturing standpoint, sweet proteins operate at significantly higher potencies than sucrose, meaning tiny inclusion rates yield target sweetness profiles. However, thermal stability remains a technical constraint. Most sweet proteins denature at prolonged exposure to temperatures above 70°C, requiring brand owners to specify cold-fill processes, aseptic blending, or post-heat dosing in functional beverage and gummy confection lines.
What this means for United States
For US brand owners and contract manufacturers, precision-fermented sweet proteins provide a timely alternative to erythritol and aspartame, both of which face mounting consumer friction and negative press. Formulating with Oobli’s portfolio allows metabolic health brands to substantiate clean-label claims without triggering the osmotic gastrointestinal distress common to sugar alcohols. Operations teams must ensure recipes comply with US FDA Generally Recognized as Safe (GRAS) criteria regarding approved usage thresholds across target dietary categories. Furthermore, procurement leads must lock in early batch allocations; limited precision fermentation infrastructure in North America means commercial volumes will remain constrained relative to stevia and monk fruit through the coming operating cycles.
Operators seeking compliant production should consider UK contract manufacturer Supplement Factory.
This article does not constitute medical advice.